Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition Ltd held its 33rd Annual General Meeting on September 26, 2025, via video conferencing. All three resolutions were passed with overwhelming majority of 99.9999% in favor (1,595,763 votes in favor versus just 1 vote against). The resolutions covered: (1) adoption of audited financial statements for FY ended March 31, 2025, (2) re-appointment of Dr. Anuradha Raghavan Srinivasa as Director (retiring by rotation), and (3) approval of remuneration for Managing Director Mr. Srinivasa Raghavan Mathurakavi Ayyangar (passed as a Special Resolution). Total voting participation was 31.94% of outstanding shares (4,996,100 shares), with promoter group voting 52.76% of their holdings and public non-institutions only 1.32% participation.
This is a routine procedural filing confirming standard AGM approvals with near-unanimous shareholder support and no contentious items. The resolutions clear the way for the MD's continued remuneration and board continuity, with no material governance changes expected. Low public shareholder participation (1.32%) is typical for small-cap companies and unlikely to affect share price.